Takeda Pharmaceutical Co. Ltd. and Seattle Genetics Inc. announced that data from the randomized phase III Alcanza clinical trial evaluating Adcetris (brentuximab vedotin) in patients with cutaneous T-cell lymphoma was published in Lancet.
A meta-analysis of previously published cancer research showed no difference in five-year and 10-year survival rates between patients who underwent radical cystectomy and a bladder-preserving combined modality treatment plan.
Ruben Mesa was named director of the UT Health Cancer Center of the UT Health Science Center San Antonio.
FDA approved the supplemental Biologics License Application for Vectibix (panitumumab) for patients with wild-type RAS (defined as wild-type in both KRAS and NRAS as determined by an FDA-approved test for this use) metastatic colorectal cancer as first-line therapy in combination with FOLFOX and as monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin, and irinotecan-containing chemotherapy.
FDA allowed marketing of ClearLLab Reagents (T1, T2, B1, B2, M), the first agency authorized test for use with flow cytometry to aid in the detection of several leukemias and lymphomas, including chronic leukemia, acute leukemia, non-Hodgkin lymphoma, myeloma, myelodysplastic syndrome and myeloproliferative neoplasms.
Novartis said the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of Kisqali (ribociclib) in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative locally advanced or metastatic breast cancer as initial endocrine-based therapy.
Novartis said the European Commission approved expanding the use of Zykadia (ceritinib) to include the first-line treatment of patients with advanced non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive.
FDA unveiled a plan to eliminate the agency's existing orphan designation request backlog and ensure response to new requests for designation with deadlines.
Claire Verschraegen was appointed director of the Division of Medical Oncology and associate director of the Translational Research Program at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. Verschraegen also holds the Diane Nye and Michael Rayden Chair in Innovative Cancer Research and serves as... […]
Gideon Blumenthal has been appointed acting deputy office director of the Office of Hematology and Oncology Products at FDA. Blumenthal is a medical oncologist and serves as the associate director of precision therapeutics in OHOP. The appointment was announced by Richard Pazdur, director of the Oncology Center of Excellence and OHOP acting director. Blumenthal previously... […]
